Virginia Tech’s Carilion School of Medicine Has Put a Special Focus on Rare Disease

Currently, 95% of rare diseases don't have an effective treatment. Progress is being made, but there is just so much ground to cover in rare disease research. Studying rare diseases…

Continue Reading Virginia Tech’s Carilion School of Medicine Has Put a Special Focus on Rare Disease
Achieving Optimal Patient Outcomes in Chronic Pain Management Across Multiple Treatments: Part One
source: pixabay.com

Achieving Optimal Patient Outcomes in Chronic Pain Management Across Multiple Treatments: Part One

Written by Sumeet Maniar, CEO at WellBrain In the U.S., 60 percent of all adults have a chronic disease, and 40 percent have two or more. Chronic diseases, which often…

Continue Reading Achieving Optimal Patient Outcomes in Chronic Pain Management Across Multiple Treatments: Part One
Study: Sofpironium Bromide Gel is Safe and Effective for Pediatric Primary Axillary Hyperhidrosis
Source: Pixabay.com

Study: Sofpironium Bromide Gel is Safe and Effective for Pediatric Primary Axillary Hyperhidrosis

A poster recently presented at the South Beach Symposium Medical Dermatology Summit by Dr. Brandon Kirsch documented that sofpironium bromide gel topical treatment can reduce how severe primary axillary hyperhidrosis…

Continue Reading Study: Sofpironium Bromide Gel is Safe and Effective for Pediatric Primary Axillary Hyperhidrosis

Primary Immunodeficiency Patients Should be Screened for Gastrointestinal Cancers Early

A research study led by Professor Beishi Zheng from Columbia University has studied the immunogenetics of gastrointestinal (GI) cancers. The Study This study demonstrated that individuals who are diagnosed with…

Continue Reading Primary Immunodeficiency Patients Should be Screened for Gastrointestinal Cancers Early
Possible Treatment for Rare Lymphomas Withdrawn from FDA Consideration
source: pixabay.com

Possible Treatment for Rare Lymphomas Withdrawn from FDA Consideration

According to a story from AJMC, the drug developer Incyte has made the decision to withdraw its New Drug Application (NDA) for its investigational therapy parsaclisib. This therapy was submitted…

Continue Reading Possible Treatment for Rare Lymphomas Withdrawn from FDA Consideration
Experimental Activated PI3K Delta Syndrome Therapy to be Submitted for Approval
source: pixabay.com

Experimental Activated PI3K Delta Syndrome Therapy to be Submitted for Approval

According to a story from pharmaphorum.com, a therapy being developed for the rare disease activated PI3K delta syndrome (APDS) is on its way to regulators for approval following promising results…

Continue Reading Experimental Activated PI3K Delta Syndrome Therapy to be Submitted for Approval